Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models

Molecular Oncology

Volumn 9, Issue 1, 2015, Pages 323-333

  Gavine, Paul R ^a   Ren, Yongxin ^b   Han, Lu ^a   Lv, Jing ^a   Fan, Shiming ^b   Zhang, Wei ^b   Xu, Wen ^b   Liu, Yuan Jie ^a   Zhang, Tianwei ^a   Fu, Haihua ^a   Yu, Yongjuan ^b   Wang, Huiying ^a   Xu, Shirlian ^a   Zhou, Feng ^b   Su, Xinying ^a   Yin, XiaoLu ^a   Xie, Liang ^a   Wang, Linfang ^b   Qing, Weiguo ^b   Jiao, Longxian ^b   Su, Weiguo ^b   Wang, Q May ^b   more..

^a ASTRAZENECA   (United Kingdom)

^b Hutchison MediPharma Limited   (China)

Author keywords

CMET; Gastric cancer; PDX; Small molecule; Tyrosine kinase inhibitor; Volitinib

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VOLITINIB; 1-(1-(IMIDAZO(1,2-A)PYRIDIN-6-YL)ETHYL)-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-(1,2,3)TRIAZOLO(4,5-B)PYRAZINE; MET PROTEIN, HUMAN; PYRAZINE DERIVATIVE; SCATTER FACTOR RECEPTOR; TRIAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CELL GROWTH; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STOMACH CANCER; TISSUE MICROARRAY; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; BIOSYNTHESIS; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; MALE; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ASIAN CONTINENTAL ANCESTRY GROUP; CELL LINE, TUMOR; COHORT STUDIES; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-MET; PYRAZINES; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TRIAZINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920385249     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.08.015     Document Type: Article

References (41)

1. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
2. Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003, 4:915-925.
3. Catenacci D.V., Henderson L., Xiao S.Y., Patel P., Yauch R.L., Hegde P., Zha J., Pandita A., Peterson A., Salgia R. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov. 2011, 1:573-579.
4. Cui J.J., McTigue M., Nambu M., et al. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1 -yl)ethanol (PF-04217903) for the treatment of cancer. J.Med. Chem. 2012, 55:8091-8109.
5. Cui, Y., Dai, G.X., Ren, Y. etal., 2013. A novel and selective c-Met inhibitor against subcutaneous xenograft and orthotopic brain tumor models (Abstract #3612).
6. Di Renzo M.F., Olivero M., Giacomini A., Porte H., Chastre E., Mirossay L., Nordlinger B., Bretti S., Bottardi S., Giordano S. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res. 1995, 1:147-154.
7. Edakuni G., Sasatomi E., Satoh T., Tokunaga O., Miyazaki K. Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol. Int. 2001, 51:172-178.
8. Fujita S., Sugano K. Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases. Jpn. J. Clin. Oncol. 1997, 27:378-383.
9. Gherardi E., Birchmeier W., Birchmeier C., Vande Woude G. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 2012, 12:89-103.
10. Go H., Jeon Y.K., Park H.J., Sung S.W., Seo J.W., Chung D.H. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J.Thorac. Oncol. 2010, 5:305-313.
11. Gu, Y., Wang, J., Yu, M.J. etal., 2013. Preclinical disposition and pharmacokinetics of volitinib (HMPL-504), a novel selective c-Met inhibitor (Poster Abstract #3371).
12. Hara T., Ooi A., Kobayashi M., Mai M., Yanagihara K., Nakanishi I. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab. Invest. 1998, 78:1143-1153.
13. Huang T.J., Wang J.Y., Lin S.R., Lian S.T., Hsieh J.S. Overexpression of the c-met protooncogene in human gastric carcinoma-correlation to clinical features. Acta Oncol. 2001, 40:638-643.
14. Humphrey P.A., Zhu X., Zarnegar R., Swanson P.E., Ratliff T.L., Vollmer R.T., Day M.L. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am. J. Pathol. 1995, 147:386-396.
15. Ichimura E., Maeshima A., Nakajima T., Nakamura T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas invitro and invivo and its prognostic significance. Jpn. J. Cancer Res. 1996, 87:1063-1069.
16. Inoue T., Kataoka H., Goto K., Nagaike K., Igami K., Naka D., Kitamura N., Miyazawa K. Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci. 2004, 95:803-808.
17. Iwai M., Matsuda M., Iwai Y. Cloning of a cancer cell-producing hepatocyte growth factor, vascular endothelial growth factor, and interleukin-8 from gastric cancer cells. InVitro Cell. Dev. Biol. Anim. 2003, 39:288-290.
18. Janjigian Y.Y., Tang L.H., Coit D.G., Kelsen D.P., Francone T.D., Weiser M.R., Jhanwar S.C., Shah M.A. MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol. Biomarkers Prev. 2011, 20:1021-1027.
19. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
20. Kuniyasu H., Yasui W., Kitadai Y., Yokozaki H., Ito H., Tahara E. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem. Biophys. Res. Commun. 1992, 189:227-232.
21. Lee H.E., Kim M.A., Lee H.S., Jung E.J., Yang H.K., Lee B.L., Bang Y.J., Kim W.H. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br. J. Cancer 2012, 107:325-333.
22. Lennerz J.K., Kwak E.L., Ackerman A., et al. METamplification identifies a small and aggressive subgroupof esophagogastric adenocarcinoma with evidenceof responsiveness to crizotinib. J.Clin. Oncol. 2011, 29:4803-4810.
23. Liu Y.J., Shen D., Yin X., et al. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. Br. J. Cancer 2014, 110:1169-1178.
24. Matsumoto K., Nakamura T. Emerging multipotent aspects of hepatocyte growth factor. J.Biochem. 1996, 119:591-600.
25. Miyata Y., Sagara Y., Kanda S., Hayashi T., Kanetake H. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin. Hum. Pathol. 2009, 40:496-504.
26. Nakajima M., Sawada H., Yamada Y., Watanabe A., Tatsumi M., Yamashita J., Matsuda M., Sakaguchi T., Hirao T., Nakano H. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999, 85:1894-1902.
27. Nakamura T., Nishizawa T., Hagiya M., Seki T., Shimonishi M., Sugimura A., Tashiro K., Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989, 342:440-443.
28. Naylor G.M., Gotoda T., Dixon M., Shimoda T., Gatta L., Owen R., Tompkins D., Axon A. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut 2006, 55:1545-1552.
29. Oliner, K., Tang, R., Anderson, A., Lan, Y., Iveson, T., Donehower, R., Jiang, Y., Dubey, S., Loh, E., 2012. Evaluation of MET-pathway biomarkers in a phase 2 study of rilotumumab plus epirubicin, cisplatin, and capecitabine in gastric/esophagogastric junction cancer, Suppl 4-iv8.
30. Park M., Dean M., Kaul K., Braun M.J., Gonda M.A., Vande Woude G. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:6379-6383.
31. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 2006, 118:3030-3044.
32. Prat M., Narsimhan R.P., Crepaldi T., Nicotra M.R., Natali P.G., Comoglio P.M. The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int. J. Cancer 1991, 49:323-328.
33. Scagliotti G.V., Novello S., von Pawel J. The emerging roleof MET/HGF inhibitors in oncology. Cancer Treat. Rev. 2013, 7:793-801.
34. Shah M.A., Wainberg Z.A., Catenacci D.V., et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One 2013, 8:e54014.
35. Stoker M., Gherardi E., Perryman M., Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987, 327:239-242.
36. Tsugawa K., Yonemura Y., Hirono Y., Fushida S., Kaji M., Miwa K., Miyazaki I., Yamamoto H. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology 1998, 55:475-481.
37. Tsujimoto H., Sugihara H., Hagiwara A., Hattori T. Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer. Virchows Arch. 1997, 431:383-389.
38. Tsuta K., Kozu Y., Mimae T., Yoshida A., Kohno T., Sekine I., Tamura T., Asamura H., Furuta K., Tsuda H. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J.Thorac. Oncol. 2012, 7:331-339.
39. Vanden Bempt I., Van Loo P., Drijkoningen M., Neven P., Smeets A., Christiaens M.R., Paridaens R., De Wolf-Peeters C. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J.Clin. Oncol. 2008, 26:4869-4874.
40. Weidner K.M., Di Cesare S., Sachs M., Brinkmann V., Behrens J., Birchmeier W. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 1996, 384:173-176.
41. Xie L., Su X., Zhang L., et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin. Cancer Res. 2013, 19:2572-2583.